BMS 986340
Alternative Names: anti-CCR8 - Bristol-Myers Squibb; BMS-986340; ONO-7427Latest Information Update: 02 Oct 2021
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 27 May 2021 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Combination therapy) in USA (Parenteral) (NCT04895709)
- 21 May 2021 Bristol-Myers Squibb plans a first-in-human phase I/II trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA in May 2021 (NCT04895709) (EudraCT2021-001188-26)